Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pet Pharm Biotech CoROCO:7762 +1.39%17 PS Ratio is 12.72 as of Aug. 14, 2026, which is 20% below its 10-year median of 15.82. GuruFocus rates ROCO:7762 with a GF Score™ of 17/100. The stock has 5 warning signs investors should review. Among 951 Drug Manufacturers companies, Pet Pharm Biotech Co ranks worse than 89.48% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Pet Pharm Biotech Co's share price is NT$50.90.
Pet Pharm Biotech Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$4.00. Hence, Pet Pharm Biotech Co's PS Ratio for today is 12.72.
Good Sign:
Pet Pharm Biotech Co Ltd stock PS Ratio (=12.38) is close to 1-year low of 11.5.
The historical rank and industry rank for Pet Pharm Biotech Co's PS Ratio or its related term are showing as below:
ROCO:7762'
s PS Ratio Range Over the Past 10 Years
Min: 7.46 Med: 15.82 Max: 26.92
Current: 12.71
During the past 4 years, Pet Pharm Biotech Co's highest PS Ratio was 26.92. The lowest was 7.46. And the median was 15.82.
ROCO:7762's PS Ratio is ranked worse than 89.48% of 951
companies
in the Drug Manufacturers industry
Industry Median: 2.33
vs ROCO:7762: 12.71
During the past 4 years, Pet Pharm Biotech Co's highest 3-Year average Revenue per Share Growth Rate was 11.40% per year. The lowest was 11.40% per year. And the median was 11.40% per year.
Pet Pharm Biotech Co (ROCO:7762) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Pet Pharm Biotech Co PS Ratio Related Terms
Pet Pharm Biotech Co PS Ratio Historical Data
* Premium members only.
The historical data trend for Pet Pharm Biotech Co's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pet Pharm Biotech Co PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Pet Pharm Biotech Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Pet Pharm Biotech Co's Share Price of today is NT$50.90.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pet Pharm Biotech Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$4.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Pet Pharm Biotech Co (ROCO:7762) has a PS Ratio of 12.72 as of Aug. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Pet Pharm Biotech Co and its competitors. This is 20% below median its historical median of 15.82. Over the past decade, Pet Pharm Biotech Co's PS Ratio has ranged from 7.46 to 26.92. According to the industry distribution chart, Pet Pharm Biotech Co ranks #851 out of 951 companies in the Drug Manufacturers industry, placing it in the top 89.5%.
Is Pet Pharm Biotech Co's PS Ratio too high?
Pet Pharm Biotech Co's current PS Ratio of 12.72 is 20% below median its 10-year median of 15.82. Over the past 10 years, this metric has ranged from a low of 7.46 to a high of 26.92. The Drug Manufacturers industry median PS Ratio is 2.33. Pet Pharm Biotech Co's value of 12.72 is 445.9% above this industry median. Based on the distribution chart, Pet Pharm Biotech Co ranks #851 out of 951 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Pet Pharm Biotech Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's PS Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Pet Pharm Biotech Co ranks #851 out of 951 companies for PS Ratio. This places Pet Pharm Biotech Co in the lower half of its industry. The industry median PS Ratio is 2.33. Pet Pharm Biotech Co's value of 12.72 is 445.9% above this benchmark. Historically, Pet Pharm Biotech Co's own PS Ratio has ranged from 7.46 to 26.92 over the past decade. While the company's 10-year median is 15.82 vs. the industry median of 2.33, Pet Pharm Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.33, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pet Pharm Biotech Co's current PS Ratio of 12.72 is 445.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Pet Pharm Biotech Co and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pet Pharm Biotech Co's current PS Ratio is 12.72, which is 20% below median its own 10-year median of 15.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current PS Ratio of 12.72. The current PS Ratio is 12.72, which is 20% below median its 10-year median of 15.82 and 445.9% above the Drug Manufacturers industry median of 2.33. Pet Pharm Biotech Co's overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current PS Ratio is 12.72 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
17GF Score
Get the complete analysis for ROCO:7762
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7762 has been successfully added to your 
